NHS to save £300m in biosimilar adalimumab deals

29-11-2018

NHS to save £300m in biosimilar adalimumab deals

p1images / iStockphoto.com

The National Health Service (NHS) England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.


NHS, National Health Service, biosimilars, biologics, cost savings, Adalimumab, AbbVie, patent expiry

More on this story

AbbVie and Pfizer in Humira licensing deal
03-12-2018

LSIPR